angiotensin ii has been researched along with cgs 35601 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Beil, ME; Bruseo, CW; Firooznia, F; Jeng, AY; Savage, P; Trapani, AJ | 1 |
| Arsenault, D; Battistini, B; Beaudoin, M; Belleville, K; Benrezzak, O; Blouin, A; Cayer, J; Daull, P; Jeng, AY; Nantel, F; Pheng, LH; Sirois, P | 1 |
2 other study(ies) available for angiotensin ii and cgs 35601
| Article | Year |
|---|---|
CGS 35601 and its orally active prodrug CGS 37808 as triple inhibitors of endothelin-converting enzyme-1, neutral endopeptidase 24.11, and angiotensin-converting enzyme.
Topics: Administration, Oral; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspartic Acid Endopeptidases; Atrial Natriuretic Factor; Blood Pressure; CHO Cells; Cricetinae; Cricetulus; Dipeptides; Endothelin-1; Endothelin-Converting Enzymes; Humans; Indoles; Injections, Intravenous; Male; Metalloendopeptidases; Neprilysin; Peptidyl-Dipeptidase A; Prodrugs; Protease Inhibitors; Rabbits; Rats; Rats, Sprague-Dawley; Time Factors; Transfection | 2004 |
Triple vasopeptidase inhibition normalizes blood pressure in conscious, unrestrained, and spontaneously hypertensive rats.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Aspartic Acid Endopeptidases; Atrial Natriuretic Factor; Benzazepines; Benzofurans; Blood Pressure; Dose-Response Relationship, Drug; Endothelin-1; Endothelin-Converting Enzymes; Hypertension; Indoles; Male; Metalloendopeptidases; Neprilysin; Nitric Oxide; Organophosphonates; Phenylalanine; Protease Inhibitors; Rats; Rats, Inbred SHR; Rats, Sprague-Dawley; Rats, Wistar; Reactive Oxygen Species | 2005 |